A study led by Gan et al. reported a therapeutic vaccine designed to counter immune‑evasive mechanisms in Epstein‑Barr virus (EBV)‑associated nasopharyngeal carcinoma (NPC). The vaccine stimulates EBV‑specific T‑cell responses and targets tumor immune checkpoints implicated in NPC progression. Preclinical data demonstrated enhanced antigen presentation and reduced tumor growth in model systems; the authors recommend advancing to early‑phase clinical trials to evaluate immunogenicity and safety in patients with EBV‑positive NPC.